[go: up one dir, main page]

ES2174064T3 - Derivados de 1,3 - dihidro - 1 - (fenilalquil) - 2h - imidazol - 2 - ona que presentan una actividad frente a pde iv y a citoquinas. - Google Patents

Derivados de 1,3 - dihidro - 1 - (fenilalquil) - 2h - imidazol - 2 - ona que presentan una actividad frente a pde iv y a citoquinas.

Info

Publication number
ES2174064T3
ES2174064T3 ES96909150T ES96909150T ES2174064T3 ES 2174064 T3 ES2174064 T3 ES 2174064T3 ES 96909150 T ES96909150 T ES 96909150T ES 96909150 T ES96909150 T ES 96909150T ES 2174064 T3 ES2174064 T3 ES 2174064T3
Authority
ES
Spain
Prior art keywords
sub
sup
optionally replaced
rent
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96909150T
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Gaston Stanislas Marcell Diels
Gil Jose Ignacio Andres
Gadea Francisco Javi Fernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2174064T3 publication Critical patent/ES2174064T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION DESCRIBE EL USO DE COMPUESTOS PARA LA FABRICACION DE UN MEDICAMENTO PARA TRATAR ANIMALES DE SANGRE CALIENTE QUE PADECEN ESTADOS DE ENFERMEDAD RELACIONADOS CON UNA ACTIVIDAD ENZIMATICA O CATALITICA ANORMAL DE LA FOSFODIESTERASA IV (PDE IV) Y/O ESTADOS DE ENFERMEDAD RELACIONADOS CON UN EXCESO FISIOLOGICAMENTE PERJUDICIAL DE CITOCINA, EN PARTICULAR ENFERMEDADES ALERGICAS, ATOPICAS E INFLAMATORIAS, POSEYENDO DICHOS COMPUESTOS LA FORMULA (I), LAS FORMAS DE N ALES DE ADICION DE ACIDOS O DE BASES FARMACEUTICAMENTE ACEPTABLES, Y LAS FORMAS ESTEREOQUIMICAMENTE ISOMERAS DE LOS MISMOS, EN LA CUAL R{SUP,1} Y R{SUP,2} SON CADA UNO INDEPENDIENTEMENTE HIDROGENO; ALQUILO C{SUB,1-6}; DIFLUOROMETILO; TRIFLUOROMETILO; CICLOALQUILO C{SUB, 3-6}; UN HETEROCICLO SATURADO DE 5, 6 O 7 ESLABONES QUE CONTIENE UNO O DOS HETEROATOMOS SELECCIONADOS ENTRE OXIGENO, AZUFRE O NITROGENO; INDANILO; BICICLO[2.2.1] LO; ARILSULFONILO; O ALQUILO C{SUB,1-10}SUSTITUIDO; R{SUP,3} ES HIDROGENO, HALO O ALQUILOXIC{SUB,1-6}; R{SUP,4} ES HIDROGENO; HALO; ALQUILO C{SUB,1-6} OPCIONALMENTE SUSTITUIDO; TRIFLUOROMETILO; CICLOALQUILO C{SUB,3-6}; CARBOXILO; ALQUILOXI(C{SUB,1-4})CARBONILO; CICLOALQUIL(C{SUB,36})AMINOCARBONILO; ARILO; HET{SUP,1}; O R{SUP,4} ES UN RADICAL DE FORMULA: FORMAR UN RADICAL BIVALENTE DE FORMULA: {SUB,2} CH{SUB,2} CANDIILO C{SUB,1-4} O ALCANDIILO C{SUB,1-4}; ADICAL BIVALENTE DE FORMULA: R{SUP,9} }OPCIONALMENTE SUSTITUIDO; ALQUIL(C{SUB,1-6})CARBONILO; ALQUILOXI(C{SUB,1-6})CARBONILO; ALQUENILO C{3-6} OPCIONALMENTE SUSTITUIDO; PIPERIDINILO OPCIONALMENTE SUSTITUIDO; ALQUIL(C{1-6})SULFONILO O ARILSULFONILO; ARILO ES FENILO OPCIONALMENTE SUSTITUIDO; HET{SUP,1} ES MORFOLINILO, O UN GRUPO PIRIDINILO, FURANILO, TIENILO, HIDROXIPIRIDINILO, IMIDAZOLILO, TIAZOLILO, OXAZOLILO, ISOQUINOLINILO, QUINOLINONILO, PIPERIDINILO O PIPERAZINILO OPCIONALMENTE SUSTITUIDOS; HET{SUP,2} ES MORFOLINILO, O UN GRUPO PIPERIDINILO, PIPERAZINILO, PIRIDINILO, FURANILO O TIENILO OPCIONALMENTE SUSTITUIDOS. LA PRESENTE INVENCION TAMBIEN TRATA DE NUEVOS COMPUESTOS QUE POSEEN ACTIVIDAD INHIBIDORA DE PDE IV Y DE CITOCINA, DE PROCEDIMIENTOS PARA SU PREPARACION Y DE COMPOSICIONES QUE INCLUYEN DICHOS NUEVOS COMPUESTOS.
ES96909150T 1995-04-06 1996-03-28 Derivados de 1,3 - dihidro - 1 - (fenilalquil) - 2h - imidazol - 2 - ona que presentan una actividad frente a pde iv y a citoquinas. Expired - Lifetime ES2174064T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95200868 1995-04-06
EP95202898 1995-10-26

Publications (1)

Publication Number Publication Date
ES2174064T3 true ES2174064T3 (es) 2002-11-01

Family

ID=26139205

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96909150T Expired - Lifetime ES2174064T3 (es) 1995-04-06 1996-03-28 Derivados de 1,3 - dihidro - 1 - (fenilalquil) - 2h - imidazol - 2 - ona que presentan una actividad frente a pde iv y a citoquinas.

Country Status (27)

Country Link
US (2) US5994376A (es)
EP (1) EP0819122B1 (es)
JP (1) JP4562101B2 (es)
KR (1) KR100406628B1 (es)
CN (1) CN1068591C (es)
AR (1) AR002732A1 (es)
AT (1) ATE214052T1 (es)
AU (1) AU702947B2 (es)
CA (1) CA2216653C (es)
CY (1) CY2328B1 (es)
CZ (1) CZ293127B6 (es)
DE (1) DE69619661T2 (es)
DK (1) DK0819122T3 (es)
ES (1) ES2174064T3 (es)
HK (1) HK1007880A1 (es)
HR (1) HRP960155A2 (es)
HU (1) HU223324B1 (es)
IL (1) IL117807A (es)
MX (1) MX9707652A (es)
MY (1) MY119254A (es)
NO (1) NO314339B1 (es)
NZ (1) NZ304877A (es)
PL (1) PL187375B1 (es)
PT (1) PT819122E (es)
SI (1) SI0819122T1 (es)
TW (1) TW332201B (es)
WO (1) WO1996031485A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
IL129298A0 (en) * 1996-10-02 2000-02-17 Janssen Pharmaceutica Nv PDE iv inhibiting 2-cyanoiminoimidazole derivatives
JP2002508001A (ja) 1997-07-10 2002-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｉｌ−５インヒビターとしての６−アザウラシル誘導体
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
EE04718B1 (et) * 1998-04-01 2006-10-16 Janssen Pharmaceutica N.V. PDE IV inhibeerivad püridiini derivaadid, nende valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon ja selle valmistamismeetod
US6118017A (en) * 1998-04-14 2000-09-12 Smithkline Beecham Corporation Substituted-(3-cyclopentyloxy-4-methoxyphenyl)-3-phenylcyanocyclobutan-1-one
WO1999052847A1 (en) * 1998-04-14 1999-10-21 Smithkline Beecham Corporation Phosphodiesterase isoenzyme denominated 4 (pde 4) inhibiting compounds
TR200101425T2 (tr) 1998-11-23 2002-02-21 Janssen Pharmaceutica N.V. IL-5 inhibe edici 6-azaurasil türevleri
ATE365723T1 (de) 1998-12-18 2007-07-15 Janssen Pharmaceutica Nv Il-5 hemmende 6-uracilderivate
AU2001290884B2 (en) * 2000-09-13 2005-12-15 Merck & Co., Inc. Alpha V integrin receptor antagonists
US20040146561A1 (en) * 2001-05-23 2004-07-29 Naoki Sakurai Compositions for promoting healing of bone fracture
MXPA03010672A (es) 2001-05-23 2004-03-02 Tanabe Seiyaku Co Composicion para el tratamiento regenerativo de enfermedades del cartilago.
US6706739B2 (en) * 2001-08-21 2004-03-16 National Health Research Institute Imidazolidinone compounds
SE0200667D0 (sv) * 2002-03-05 2002-03-05 A & Science Invest Ab Novel use of cytokine inhibitors
GB0326407D0 (en) * 2003-11-12 2003-12-17 Glaxo Group Ltd Chemical compounds
GB0412865D0 (en) * 2004-06-09 2004-07-14 Glaxo Group Ltd Chemical compounds
KR100682199B1 (ko) * 2004-07-05 2007-02-12 동화약품공업주식회사 알러지성 염증 질환의 예방 및 치료용 조성물
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
JP2009525269A (ja) * 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
US7674811B2 (en) 2006-03-14 2010-03-09 Ranbaxy Laboratories Limited 5-lipoxygenase inhibitors
US7390772B2 (en) * 2006-05-18 2008-06-24 International Flavor & Fragrances Inc. 1-phenyl-spiro[2.5]octane-1-carbonitrile analogues their use in fragrance formulations
WO2008157425A2 (en) * 2007-06-14 2008-12-24 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
KR101512548B1 (ko) 2010-03-12 2015-04-15 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
KR20170139074A (ko) 2015-04-24 2017-12-18 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL285394A (es) * 1961-11-17
US3184060A (en) 1963-02-13 1965-05-18 Owens Illinois Glass Co Packaging tacky latex emulsion paints in containers manufactured from polyolefinic maerials
WO1992007567A1 (en) * 1990-11-06 1992-05-14 Smithkline Beecham Corporation Imidazolidinone compounds
CA2400368A1 (en) * 1992-12-02 1994-06-09 Allen J. Duplantier Catechol diethers as selective pde iv inhibitors
TW263495B (es) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
TW332201B (en) 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives

Also Published As

Publication number Publication date
AR002732A1 (es) 1998-04-29
NO314339B1 (no) 2003-03-10
EP0819122B1 (en) 2002-03-06
CN1068591C (zh) 2001-07-18
HRP960155A2 (en) 1997-10-31
PT819122E (pt) 2002-08-30
IL117807A (en) 2001-06-14
IL117807A0 (en) 1996-08-04
AU5275596A (en) 1996-10-23
CA2216653C (en) 2009-05-26
CZ293127B6 (cs) 2004-02-18
DE69619661D1 (de) 2002-04-11
WO1996031485A1 (en) 1996-10-10
HK1007880A1 (en) 1999-04-30
PL187375B1 (pl) 2004-06-30
KR100406628B1 (ko) 2004-05-31
AU702947B2 (en) 1999-03-11
US6403805B1 (en) 2002-06-11
MX9707652A (es) 1997-11-29
JPH11503136A (ja) 1999-03-23
KR19980703449A (ko) 1998-11-05
PL322654A1 (en) 1998-02-16
NO974602D0 (no) 1997-10-06
HUP9801575A2 (hu) 1999-01-28
DK0819122T3 (da) 2002-07-01
EP0819122A1 (en) 1998-01-21
CZ314997A3 (cs) 1998-12-16
HU223324B1 (hu) 2004-06-28
US20020068830A1 (en) 2002-06-06
CA2216653A1 (en) 1996-10-10
NZ304877A (en) 1999-06-29
US5994376A (en) 1999-11-30
CN1181072A (zh) 1998-05-06
SI0819122T1 (en) 2002-06-30
JP4562101B2 (ja) 2010-10-13
ATE214052T1 (de) 2002-03-15
TW332201B (en) 1998-05-21
HUP9801575A3 (en) 1999-03-01
NO974602L (no) 1997-10-06
CY2328B1 (en) 2004-02-06
MY119254A (en) 2005-04-30
DE69619661T2 (de) 2002-10-31

Similar Documents

Publication Publication Date Title
ES2174064T3 (es) Derivados de 1,3 - dihidro - 1 - (fenilalquil) - 2h - imidazol - 2 - ona que presentan una actividad frente a pde iv y a citoquinas.
FR2809396B1 (fr) Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2692575B1 (fr) Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
BRPI0408990A (pt) derivados de pirimidin-4-ona e sua utilização como moduladores da p38-cinase
ES2142861T3 (es) Derivados de 4-(1h-2-metilimidazo(4,5-c)piridinilmetil)fenilsulfonamida como antagonistas del paf.
DE60327652D1 (de) Diarylureidoderivate und deren medizinische verwendung
ES2136291T3 (es) Derivados de pirimidina.
ES2160602T3 (es) Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria.
DE60042831D1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
DE69413118D1 (de) Benzolsulfonamid-Derivate zur Behandlung der Blaseninstabilität
ATE67756T1 (de) N-substituierte 3-piperidin- oder 3pyridincarbons|uren und deren derivate.
ES2297837T3 (es) Derivados de 1,3-dihidro-1-(fenilalquenil)-2h-imidazol-2-ona que tienen actividad inhibidora de pde iv y de citoquina.
DK189982A (da) Oligosaccharider med korte kaeder der har biologiske egenskaber deres fremstilling og deres anvendelse som laegemidler
ATE80616T1 (de) Prostaglandin e1-derivate und ihre therapeutische anwendung.
ES2124861T3 (es) Derivados de aminoacidos y su utilizacion como inhibidores de la encefalinasa.
ATE3552T1 (de) Verfahren zur herstellung von phosphono-hydroxy- essigsaeure und salzen derselben sowie diese enthaltende autivirale mittel.
DE60111553D1 (de) Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
PT77238B (de) Substituierte tert.-butanol-derivate verfahren zu ihrer herstellung und diese enthaltende antimykotische mittel
ATE10841T1 (de) Tricyclische thiazolyloxamidsaeuren und derivate, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel.
DK288787A (da) Kondenserede imidazo-heterocycliske forbindelser, fremgangsmaade til deres fremstilling, og deres anvendelse som laegemidler
ATE63541T1 (de) N-phenylethylaminoalkyl-benzamide als antiarrhythmische mittel.
EP0913396A3 (de) Sulfonamid-substituierte Benzopyranderivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE69400352D1 (de) 3- oder 4-Glykosyloxybenzopyranderivat und dieses enthaltende antiallergisches Mittel
ES2162022T3 (es) Derivados de tiol con actividad inhibidora de la metalopeptidasa.
ES2055440T3 (es) Derivados del acido quinurenico, su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 819122

Country of ref document: ES